Gene therapy breakthrough targets Hard-to-Treat HER2 cancers

NCT ID NCT07192432

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 32 times

Summary

This early-stage trial tests a new gene therapy called VNX-202 in 27 adults with HER2-positive solid tumors. The study aims to see if the treatment is safe and can shrink tumors or slow their growth. Participants must have advanced cancer that has worsened after standard treatments or early-stage cancer at high risk of return.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 EXPRESSING SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI Denver DDU at HealthOne

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 90067, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.